New Approaches to Drug Discovery

  • Ulrich Nielsch
  • Ulrike Fuhrmann
  • Stefan Jaroch

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 232)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Jörg Eder, Paul L. Herrling
    Pages 3-22
  3. Robert Adams, Michael Steckel, Barbara Nicke
    Pages 25-41
  4. Eric F. van Herwerden, Roderich D. Süssmuth
    Pages 91-123
  5. Michael S. Lawless, Marvin Waldman, Robert Fraczkiewicz, Robert D. Clark
    Pages 139-168
  6. Diana Behrens, Jana Rolff, Jens Hoffmann
    Pages 203-221
  7. Daniela Fliegner, Christoph Gerdes, Jörg Meding, Johannes-Peter Stasch
    Pages 223-234
  8. Claudia Stark, Thomas Steger-Hartmann
    Pages 261-283
  9. Patricia Carrigan, Thomas Krahn
    Pages 285-311
  10. Jörg Lippert, Rolf Burghaus, Lars Kuepfer, Bart Ploeger, Stephan Schaller, Walter Schmitt et al.
    Pages 313-329
  11. Back Matter
    Pages 331-341

About this book


This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.


Biologics Drug characterization Drug discovery Drug optimization Drug targets Preclinical research

Editors and affiliations

  • Ulrich Nielsch
    • 1
  • Ulrike Fuhrmann
    • 2
  • Stefan Jaroch
    • 3
  1. 1.Drug Discovery-Cross Indication PlatformBayer Pharma AGWuppertalGermany
  2. 2.Drug Discovery-Cross Indication PlatformBayer Pharma AGBerlinGermany
  3. 3.Drug Discovery-Global External Innovation & AlliancesBayer Pharma AGBerlinGermany

Bibliographic information